Francisco Chacón-Lozsán: Cytokine Storm Is Not Just Inflammation, It Is Organ Failure in Motion
Francisco Chacón-Lozsán, Fellow at World Extreme Medicine, Member of European Society of Intensive Care Medicine (ESICM) and American College of Cardiology, shared on LinkedIn about a recent article by Raffaele Merola et al, published in Journal of Intensive Medicine:
” ‘Cytokine storm’ is not just inflammation, it is organ failure in motion.
A new review reframes ARDS beyond lung mechanics:
- ARDS is not only a respiratory disease
- It is a systemic immune catastrophe
What really happens in ARDS?
- Dysregulated immune activation leading to excess cytokine release
- Breakdown of the alveolar – capillary barrier
- Spillover into systemic circulation
The lung becomes the source and amplifier of systemic inflammation
Why patients die is NOT hypoxemia alone
The real driver:
Multiorgan dysfunction syndrome (MODS)
Cytokines don’t stay in the lungs:
- Brain leads to BBB disruption and neuroinflammation
- Heart leads to decreased contractility and arrhythmias
- Bone marrow leads to cytopenias
- Kidney leads to AKI, microvascular ischemia
- Liver leads to coagulopathy, DIC
ARDS becomes a whole-body disease
Not all ARDS is the same
Two key phenotypes:
Hyperinflammatory
- High IL-6, IL-8, TNF
- More shock, higher mortality
- Worse ventilator outcomes
Hypoinflammatory
- Lower cytokines
- Better outcomes
Same syndrome. Different biology. Different response to therapy.
Therapy: still behind the biology
- Lung – protective ventilation leads to cornerstone
- Corticosteroids leads to evidence-supported
- Cytokine removal, biologics, MSCs leads to promising but inconsistent
The problem: we treat ARDS as one diseas
The future is precision critical care
We should move:
From:
- ‘All ARDS patients get the same protocol’
To:
- Biomarker-guided therapy
- Subphenotype – driven interventions
- Timing-based immunomodulation
Clinical takeaway
If we don’t identify who is in a cytokine storm, we will continue to dilute effective therapies in heterogeneous populations.
ARDS is not failing because treatments don’t work.
It’s failing because we treat the wrong patients, at the wrong time, with the wrong strategy.”
Title: Cytokine storm in acute respiratory distress syndrome
Authors: Raffaele Merola, Patricia R.M. Rocco, Vito Marco Ranieri, Denise Battaglini
Stay updated with Hemostasis Today.
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation
-
Aug 13, 2026, 16:25Connie Montgomery: Bridging the Gap Between Patients, Culture and Clinical Trials
-
Aug 13, 2026, 16:16Isabella Presch: A New AI Approach to Protein Engineering